<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03135457</url>
  </required_header>
  <id_info>
    <org_study_id>NL59191.018.16</org_study_id>
    <nct_id>NCT03135457</nct_id>
  </id_info>
  <brief_title>TACO Crossover TRIAL</brief_title>
  <official_title>A Cross-over Randomized Controlled Trial; Pulmonary Edema Detection After Fluid Loading With Blood Versus Saline in Patients After CABG</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, prospective crossover randomized controlled trial to investigate
      wether TACO is solely hydrostatic pressure overload or arises from a combination of
      hydrostatic pressure overload and capillary leakage, by investigating the difference in
      change in static pressure parameters (PCWP), dynamic volume parameters (PICCO) as indirect
      measurements of volume status and capillary leakage after autologous transfusion or saline
      infusion. The investigators will estimate effective circulating volume following autologous
      transfusion or saline infusion. Furthermore, the investigators will investigate the effect of
      fluid loading on the microcirculation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Coronary arterial bypass grafting surgery patients with reduced left ventricular function
      will be allocated to either infusion of 300mL saline with a subsequent autologous RBC (cell
      saver) transfusion of 300 mL at a rate of 10mL/min, or the same in the reversed order. Prior
      to start of the intervention, 15 minutes following start of infusion and a the end of
      infusion, the investigators will measure right-ventricular pressure and wedge pressure
      (PCWP), as well as extravascular lung water index (EVLWI) and CO estimation through PICCO®
      and Pulmonary Artery Catheter. The investigators will identify fluid responsiveness by
      performing a passive leg raise test (PLR). The investigators aim to measure total vessel
      density (TVD), perfused vessel density (PVD), proportion of perfused vessels (PPV),
      microvascular flow index (MFI), and blood vessel diameters (Øbv) from the oral
      microcirculation by CytoCam microscope system. The investigators will estimate the effective
      circulating blood and plasma volume through dilutional infusion of indocyanine green prior to
      initial infusion, between and at the end of subsequent infusion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 16, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Open-label, prospective cross-over randomized controlled trial.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Masking of investigator is not possible due to nature of intervention.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Hydrostatic pressure overload</measure>
    <time_frame>1 hour</time_frame>
    <description>Hydrostatic pressure overload defined as delta pulmonary capillary wedge pressure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Capillary leakage</measure>
    <time_frame>1 hour</time_frame>
    <description>Capillary leakage defined as delta extra vascular lung water index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output</measure>
    <time_frame>1 hour</time_frame>
    <description>Volume overload measured by cardiac output</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>1 hour</time_frame>
    <description>Volume overload measured by mean arterial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse pressure variation</measure>
    <time_frame>1 hour</time_frame>
    <description>Volume overload measured by pulse pressure variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke volume variation</measure>
    <time_frame>1 hour</time_frame>
    <description>Volume overload measured by stroke volume variation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra vascular lung water index</measure>
    <time_frame>1 hour</time_frame>
    <description>Volume overload measured by extra vascular lung water index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic vascular resistance</measure>
    <time_frame>1 hour</time_frame>
    <description>Volume overload measured by systemic vascular resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colloid osmotic pressure</measure>
    <time_frame>1 hour</time_frame>
    <description>Colloid osmotic pressure measured by membrane colloid osmometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated circulating volume</measure>
    <time_frame>1 hour</time_frame>
    <description>Estimated circulating blood volume measured by indocyanine green</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated circulating volume</measure>
    <time_frame>1 hour</time_frame>
    <description>Estimated circulating plasma volume measured by indocyanine green</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculation</measure>
    <time_frame>1 hour</time_frame>
    <description>Total vessel density in the sublingual microcirculation measured by Cytocam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculation</measure>
    <time_frame>1 hour</time_frame>
    <description>Perfused vessel density in the sublingual microcirculation measured by Cytocam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculation</measure>
    <time_frame>1 hour</time_frame>
    <description>Proportion of perfused vessels in the sublingual microcirculation measured by Cytocam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculation</measure>
    <time_frame>1 hour</time_frame>
    <description>Microvascular flow index in the sublingual microcirculation measured by Cytocam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microcirculation</measure>
    <time_frame>1 hour</time_frame>
    <description>Blood vessel diameters in the sublingual microcirculation measured by Cytocam</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluid responsiveness</measure>
    <time_frame>1 hour</time_frame>
    <description>Fluid responsiveness defined by Passive Leg Raise test (increase in cardiac output &gt; 10%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TACO</measure>
    <time_frame>6 hours</time_frame>
    <description>Transfusion associated circulatory overload criteria 6 hours after infusion of autologous blood transfusion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Transfusion-associated Circulatory Overload</condition>
  <condition>Blood Transfusion Reaction</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive infusion of 300mL saline with a subsequent autologous Red Blood Cells (RBC) transfusion of 300 mL at a rate of 10mL/min</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will receive infusion of 300mL autologous RBC with a subsequent saline transfusion of 300 mL at a rate of 10mL/min</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous RBC transfusion</intervention_name>
    <description>Autologous RBC transfusion 300ml 10 ml/min</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Saline transfusion</intervention_name>
    <description>Saline transfusion 300ml 10ml/min</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;18 years

          2. Elective (non-redo) coronary arterial bypass grafting surgery

          3. Reduced left ventricular ejection fraction (&lt;55%)

          4. Transfusion of autologous blood (cell saver blood, 300ml, HCT60%, 30min)

          5. Informed consent

        Exclusion Criteria:

          1. Patients with no indication for autologous RBC transfusion

          2. Patients with pulmonary hypertension, congenital heart disease, mitral or tricuspid
             valve disease.

          3. Contraindications for PAC placement; coagulopathy, bundle branch block, defibrillator
             or pacemaker (risk of displacement). External pacemaker placed during surgery is no
             exclusion criterium.

          4. Patients for acute, non-elective surgery

          5. Chronic kidney disease stage 4 or higher (eGFR &lt; 30)

          6. Massive transfusion

          7. Previous randomization in the current trial

          8. Postoperative ongoing bleeding

          9. Bypass duration &gt; 2 hours

         10. Infusion of high dose corticosteroids

         11. Hemodynamic instability with a mean arterial pressure (MAP) &lt; 60 mmHg, central venous
             pressure &gt; 20 mmHg or dependence on high dosages of inotropic drugs after admittance
             to the ICU

         12. Severe arrhythmias

         13. Development of severe pulmonary edema during infusion of autologous blood or saline.

         14. Elevated liver enzymes

         15. Iodine allergy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander Vlaar, MD PhD MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander PJ Vlaar, MD PhD MBA</last_name>
    <phone>0031-20-5669111</phone>
    <email>a.p.vlaar@amc.uva.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academisch Medisch Centrum - Universiteit van Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander PJ Vlaar, MD PhD MBA</last_name>
      <email>a.p.vlaar@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Bart F Geerts, MD PhD MSc</last_name>
      <email>b.f.geerts@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Joachim J Bosboom, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alexander PJ Vlaar, MD PhD MBA</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bart F Geerts, MD PhD MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert B Klanderman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Delaney M, Wendel S, Bercovitz RS, Cid J, Cohn C, Dunbar NM, Apelseth TO, Popovsky M, Stanworth SJ, Tinmouth A, Van De Watering L, Waters JH, Yazer M, Ziman A; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016 Dec 3;388(10061):2825-2836. doi: 10.1016/S0140-6736(15)01313-6. Epub 2016 Apr 12. Review.</citation>
    <PMID>27083327</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 26, 2017</study_first_submitted>
  <study_first_submitted_qc>April 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2017</study_first_posted>
  <last_update_submitted>September 4, 2017</last_update_submitted>
  <last_update_submitted_qc>September 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>A.P.J. Vlaar</investigator_full_name>
    <investigator_title>MD PhD MBA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Transfusion Reaction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

